Merck Expands Kidney Cancer Treatment with FDA Approval of KEYTRUDA and WELIREG Combination
Merck (MRK) announced that the U.S. Food and Drug Administration approved its cancer drug KEYTRUDA, along with a new formulation called KEYTRUDA QLEX, in combination with WELIREG for certain kidney cancer patients post-surgery who are at higher risk of recurrence.
Tickers: $MRK
Topics: FDA KEYTRUDA kidney cancer WELIREG